Latest news with #medRxiv
Time Magazine
08-05-2025
- Health
- Time Magazine
Richard Sever
When Richard Sever co-founded a medical research preprint site—where scientists can share early versions of their research with the public for free—called medRxiv in 2019, he couldn't have foreseen what was coming. By March 2020, the site was getting hundreds of new research paper submissions every week—first from China, then Italy, then the UK and US, mirroring the spread of COVID-19 cases around the world. Sever and his team were working 14-hour days, 7 days a week to screen each paper to verify the science, catch plagiarism, protect patient privacy, and eliminate misinformation. In those days, medRxiv and bioRxiv, a biology research preprint server Sever co-founded in 2013, hosted 25% of all COVID-19 research. To date, bioRxiv and medRxiv have published more preprints than any other biology server. 'We saw these bizarre scenarios where a paper would come out about a new variant of COVID on bioRxiv and medRxiv and you knew how important it was in real time,' says Sever. Had that paper appeared in a journal several months later after peer review, he noted, the findings would no longer have been relevant. One trial that found dexamethasone effective for treating severe COVID went on medRxiv for many weeks before it was in a journal. 'The day it went up, you could see the data, people could read it, physicians around the world could put that into practice,' Sever says. The chaos during COVID-19 proved the importance of sites like medRxiv and bioRxiv in communicating research in an increasingly digital world, and challenged a decades-old publishing and peer review process to modernize. In 2024, the two preprint platforms, which had been embedded within the infrastructure of the well-respected Cold Spring Harbor Laboratory since their inception, announced that they would be breaking out to stand on their own, overseen by an independent non-profit organization, openRxiv. Sever serves as openRxiv's chief science and strategy officer, and works to make the platform an accessible and open place for researchers of all backgrounds to share good science.
Yahoo
24-04-2025
- Business
- Yahoo
Gameto Announces First U.S. Clinical Site Open for Enrollment in Fertilo Study
- Reproductive Fertility Center in Corona, CA to offer novel investigational platform for fertility treatment AUSTIN, Texas, April 24, 2025--(BUSINESS WIRE)--Gameto, a clinical-stage biotech company developing iPSC-based therapies to transform fertility care, today announced that the Reproductive Fertility Center in Corona, CA, led by Dr. Daniel Williams, is now open for patient enrollment in Gameto's first clinical study of Fertilo in the United States. Fertilo is an investigational platform designed to reduce the burden of ovarian stimulation for women undergoing fertility treatment. By using engineered ovarian support cells to promote egg maturation outside of the body, Fertilo aims to shorten or eliminate the need for weeks of hormone injections typically required in conventional in vitro fertilization (IVF) cycles. The trial at Reproductive Fertility Center represents a significant milestone as Gameto expands Fertilo's clinical development across leading fertility centers in the U.S. In addition to this center in California, Gameto expects to open over a dozen additional clinical sites in the coming weeks as part of its U.S. Fertilo study rollout. New sites are anticipated across key states including Florida, Texas, New York, and Connecticut, with more locations to follow. "Opening our first U.S. clinical site for our pivotal study, is an exciting step forward for Gameto and for the future of fertility care," said Dr. Dina Radenkovic, CEO & Co-Founder, Gameto. "We are proud to partner with Dr. Williams and his outstanding team at Reproductive Fertility Center to offer women a new investigational option aimed at making fertility treatment faster, easier, and less invasive." The Fertilo study will evaluate the ability of engineered ovarian support cells to mature patient eggs ex vivo, with the goal of achieving fertilization and embryo development after a much shorter period of ovarian stimulation. Patients participating in the study will receive personalized monitoring and care at Reproductive Fertility Center, one of Southern California's leading fertility clinics. "We are excited to be the first clinical site in the U.S. enrolling patients in this innovative study," said Dr. Daniel Williams, Medical Director of Reproductive Fertility Center. "Our mission has always been to provide patients with access to the latest advances in reproductive medicine. Fertilo has the potential to offer a safer, simpler alternative for women who want to preserve their fertility or start a family. And with the expertise of our clinical team, including Dr. James P. Lin and Dr. Susan Nasab, we are proud to contribute to advancing this important research." Gameto recently published a preprint on medRxiv demonstrating that Fertilo can effectively promote egg maturation, leading to a higher number of viable embryos and significantly improved pregnancy success rates. In mini-stimulation (mini-stim) cycles supplemented with Fertilo, patients achieved a 44% pregnancy rate per cycle after the first embryo transfer, more than double the success rate typically observed with conventional in vitro maturation (IVM), which stands at 20%. Patients treated with Fertilo also had more viable embryos available for transfer, further enhancing their chances of conception. The company plans to open additional clinical sites in its pivotal U.S. Phase 3 clinical trial (NCT06858111) of Fertilo, a first-in-class iPSC-derived therapy. Individuals interested in joining the study can learn more at About FertiloFertilo is Gameto's ovarian support cell (OSC) product that matures eggs outside the body using iPSC-derived cells. By mimicking the natural ovarian environment in vitro, Fertilo enables replacement of ~80% of hormone injections and shortens IVF or egg freezing cycles from 10-14 days to just 2-3 days. This approach offers a potentially safer, less invasive alternative to traditional IVF, significantly reducing patient burden and the risk of ovarian hyperstimulation. About GametoGameto is a biotechnology company developing novel solutions for women's health, starting with infertility. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys. Gameto's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and founder of one of North America's largest fertility networks Prelude Fertility, Martin Varsavsky, as Chairman. For more information, go to or follow us on Twitter and Instagram @gametogen and on LinkedIn. View source version on Contacts InvestorKylie Jordankylie@ MediaKimberly HaKKH 917-291-5744 Sign in to access your portfolio
